A new analysis has identified 86 crop-protection substances that could face a heightened risk of failing renewal under proposed EU data rules. The figure gives growers and distributors the first concrete measure of how a regulatory procedural change, rather than a safety finding, could shrink the European toolbox of plant protection products.

Why does a data rule matter for approvals?

The substances at issue are existing active ingredients (the biologically active chemicals in herbicides, fungicides and insecticides) that will at some point need to pass through the EU's renewal process. Renewal requires registrants to resubmit a full dossier of studies proving the substance still meets safety standards.

The proposed rules change what data regulators demand and how that data is assessed. Where a dossier cannot satisfy the new requirements — because studies are missing, outdated, or no longer acceptable to evaluators — the substance can fail renewal regardless of its field performance.

That is the mechanism behind the 86-substance list. The analysis works through the proposed requirements against the dossiers of approved substances and flags those where the gap between what exists and what would be required is widest.

What does this change for farmers?

For growers, the significance is planning, not immediate action. None of the 86 substances loses approval today. Each one's fate depends on when its current approval expires, whether the manufacturer chooses to invest in the additional studies, and how member states vote when the renewal decision reaches a committee stage.

The practical risks are familiar from previous withdrawals:

• Loss of actives with no direct substitute, particularly in minor crops where few alternatives are registered.
• Increased reliance on a narrower set of chemistry, which raises resistance-management concerns.
• Supply decisions by manufacturers who judge the cost of new data packages too high against expected returns.

What should growers and agronomists watch next?

The critical variable is the fate of the proposed rules themselves. Until they are adopted in final form, the analysis represents risk, not outcome. Stakeholders should track the legislative passage of the data requirements, the publication of any revised list as dossiers are reviewed, and renewal deadlines in the coming approval cycle for the flagged substances.

By James Calloway